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BACKGROUND: Colonoscopic surveillance provides the best practical means for preventing colorectal cancer (CRC) in inflammatory
bowel disease (IBD) patients. Strong evidence for improved survival from surveillance programmes is sparse.
METHOD: The aim of this study was to compare tumour stage and survival of IBD patients with CRC who were a part of a surveillance
programme with those who were not. A nationwide pathology database (PALGA (pathologisch anatomisch landelijk
geautomatiseerd archief)) was consulted to identify IBD patients with CRC treated in all eight university hospitals in The
Netherlands over a period of 15 years. Patients were assigned to the surveillance group when they had undergone one or more
surveillance colonoscopies before a diagnosis of CRC. Patients who had not undergone surveillance served as controls. Tumour stage
and survival were compared between the two groups.
RESULTS: A total of 149 patients with IBD-associated CRC were identified. Twenty-three had had colonoscopic surveillance before
CRC was discovered. The 5-year CRC-related survival rate of patients in the surveillance group was 100% compared with 74% in the
non-surveillance group (P¼ 0.042). In the surveillance group, only one patient died as a consequence of CRC compared with 29
patients in the control group (P¼ 0.047). In addition, more early tumour stages were found in the surveillance group (P¼ 0.004).
CONCLUSIONS: These results provide evidence for improved survival from colonoscopic surveillance in IBD patients by detecting CRC
at a more favourable tumour stage.
British Journal of Cancer (2009) 101, 1671–1675. doi:10.1038/sj.bjc.6605359 www.bjcancer.com
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The increased risk of colorectal cancer (CRC) in patients with
inflammatory bowel disease (IBD) has been well documented
(Eaden et al, 2001; Jess et al, 2005). In an effort to detect dysplasia
or early stage cancer, it is advised that patients should enter a
surveillance programme according to the guidelines of the
American Gastroenterological Association (Winawer et al, 2003)
or of the British Society of Gastroenterology (Eaden and Mayberry,
2002). Although not flawless, it is currently the best tool available
to detect early-stage neoplasia or prevent CRC in patients with
IBD. The level of evidence for its effectiveness, however, is low and
has only been studied in patients with ulcerative colitis (Collins
et al, 2006). The ideal setup to evaluate the effectiveness of
surveillance programmes would be a randomised trial with CRC-
related mortality as the primary end point. Unfortunately, such
a trial does not exist and probably never will be performed
because of practical and ethical considerations (Bernstein, 1998).
Therefore, retrospective studies are probably the best alternative to
assess the effectiveness of colonoscopic surveillance.
A recent review by the Cochrane Collaboration (Collins et al, 2006)
identified three studies that presented indirect evidence for improved
survival from colonoscopic surveillance in ulcerative colitis patients
(Lashner et al, 1990; Choi et al, 1993; Karlen et al, 1998). These
studies either had a low number of patients with IBD-associated CRC
or a low number of patients in a surveillance programme, which
prevented the outcomes from reaching statistical significance.
We recently reported on time intervals between the diagnosis of
IBD and CRC in a large cohort of patients with IBD-associated
CRC, collected from all university medical centres in The
Netherlands using a nationwide pathology database (Lutgens
et al, 2008). The aim of this retrospective study was to compare
tumour stage and survival in this cohort between patients who
were a part of a surveillance programme with those who were not.
MATERIALS AND METHODS
Search strategy
Pathologisch anatomisch landelijk geautomatiseerd archief
(PALGA), the nationwide network and registry of histo- and
Received 16 June 2009; revised 27 August 2009; accepted 4 September
2009; published online 13 October 2009
*Correspondence: Dr FP Vleggaar, University Medical Center Utrecht,
Department of Gastroenterology and Hepatology, Heidelberglaan 100,
3584 CX Utrecht, The Netherlands.
E-mail: f.vleggaar@umcutrecht.nl
British Journal of Cancer (2009) 101, 1671 – 1675
& 2009 Cancer Research UK All rights reserved 0007 – 0920/09 $32.00
www.bjcancer.com
C
li
n
ic
a
l
S
tu
d
ie
s
cytopathology (Casparie et al, 2007), contains pathology reports
generated in the Netherlands dating back to 1971. These reports
are concluded with diagnostic terms in line with SNOMED
(systematised nomenclature of medicine) terminology and were
used to search for patients with IBD-associated CRC. PALGA
achieved nationwide coverage in 1990. For that reason, a search for
the time period between January 1990 and July 2006 in all eight
Dutch university medical centres for synchronous or metachro-
nous diagnoses of IBD and CRC was conducted. The following
combinations of search terms were used: ulcerative colitis and
adenocarcinoma; Crohn’s disease and adenocarcinoma; colon and
colitis and adenocarcinoma; colon and inflammation and adeno-
carcinoma; colon and chronic inflammation and adenocarcinoma;
colon and idiopathic colitis and adenocarcinoma; colon and
adenocarcinoma and active inflammation. Only patients with a
confirmed histological diagnosis of inflammatory bowel disease
and CRC were included.
The PALGA search engine ensures patient privacy by supplying
anonymous data. Only the patient’s own physician was able to link
PALGA identification codes to real patient identification codes.
The treating physician in each university medical centre subse-
quently supplied only the first author with anonymous data. No
personal patient data were recorded.
Data extraction
The following data were collected from patient charts by one
investigator (ML): type of IBD, gender, age at IBD diagnosis, age at
CRC diagnosis, date of onset of symptoms, date of IBD diagnosis,
date of CRC diagnosis, date of start of surveillance, intervals
between surveillance colonoscopies, date of end of follow-up, cause
of death, tumour stage in the resection specimen or by radiological
imaging if the patient was not operated, concurrent primary
sclerosing cholangitis, existing co-morbidity, history of smoking
and alcohol use, and history of 5-amino-salycilic acid (5-ASA)
medication. A diagnosis of primary sclerosing cholangitis had to
be made with retrograde cholangiopancreatography, magnetic
resonance cholangiopancreatography, or liver biopsy. Co-morbid-
ity was defined as severe cardiac, severe pulmonary, severe renal,
severe liver dysfunction, or malignancy other than CRC.
Surveillance criterion
A patient was assigned to the surveillance group when before CRC
diagnosis at least one or more surveillance colonoscopies at
regular intervals (every 1 –3 years) had been performed. The
remainder of the patients were assigned to the non-surveillance
group and served as controls. The surveillance quality had to meet
the standard that is described by current guidelines (Eaden and
Mayberry, 2002; Winawer et al, 2003). This entails the intent to
detect neoplasia by taking four random biopsies every 10 cm of the
colon in addition to targeted biopsies of suspicious areas during
that colonoscopy. No attempt was made to compare surveillance
colonoscopies with each other on the basis of frequency or number
of biopsies.
Patients who were under regular surveillance for multiple years,
but for some reason had skipped one colonoscopy, were only
assigned to the surveillance group if the longest lapse since the last
colonoscopy was 3 years or less. To minimise selection bias,
patients in whom the diagnosis of CRC was made by colonoscopy
according to surveillance protocol for the first time (thus not yet
enrolled in a surveillance programme) were not assigned to the
surveillance group when the reason for this first surveillance
colonoscopy was new or recurrent symptoms of disease.
Statistical analysis
The w2 test, Fisher’s exact test, and Student’s t–test were used
where appropriate to compare patient characteristics between the
two groups. Kaplan– Meier (Kaplan and Meier, 1958) and
Cox regression analyses were used for survival calculations.
The primary study end points were CRC related or overall death.
The end of follow-up was either the end of study date (1 July 2006)
or date of death. When a patient was lost to follow-up, the date
of the last visit to the hospital was recorded as end of follow-up.
The Tarone –Ware test of equality of survival distributions was
used to compare differences between survival curves. Tumour
stages were grouped according to the sixth edition staging system
of the American Joint Committee on Cancer (Greene et al, 2002;
Sobin and Wittekind, 2002). The w2 test and Fisher’s exact test
were used where it was appropriate to compare tumour stages
between the surveillance and non-surveillance groups. P-values
o0.05 were considered to be statistically significant. SPSS software
for windows version 14.0, SPSS Inc, was used for all statistical analyses.
RESULTS
Our search identified 166 patients, of whom 17 were excluded. The
reasons for exclusion were: no histological confirmed diagnosis of
IBD (n¼ 11), suspected adenocarcinoma in the biopsy sample that
could not be reproduced in the colectomy specimen (n¼ 2), a
focus of micro-carcinoid instead of adenocarcinoma (n¼ 2),
unknown date of IBD diagnosis (n¼ 1), and occurrence of CRC
before IBD was diagnosed (n¼ 1). This left 149 cases for analysis.
Twenty-three patients had undergone one or more surveillance
colonoscopies before the diagnosis of CRC and were analysed as
the surveillance group. Surveillance was started after a median of
14.3 (std 8.0) years after histological diagnosis of IBD. CRC
developed after a median of 6.4 years (range 1–21) after initiation
of surveillance. The remaining 126 patients were assigned to the
non-surveillance control group. Patient characteristics are shown
in Table 1. No statistically significant differences were found
between the two groups for any of the variables.
Follow-up after a diagnosis of CRC was complete for 114 (79%)
patients until the study end date or death. Thirty-one (21%)
patients were lost to follow-up. Four of these 31 patients, two in the
surveillance group and two in the non-surveillance group, were
lost to follow-up immediately after diagnosis of CRC and were
therefore excluded from the survival analyses.
Overall, 42 of 145 (29%) patients died. The cause of death was
directly related to metastasised CRC in 30 patients. Of the
remaining, six patients died from metastasis of a different primary
tumour (cholangiocarcinoma (n¼ 3), renal cell tumour (n¼ 1),
urothelial carcinoma (n¼ 1), primary tumour of the stomach
(n¼ 1)), and another six patients died after complications related
to colectomy. In the surveillance group, only one patient died
because of CRC compared with 29 patients in the non-surveillance
control group (P¼ 0.047). The overall 5-year survival rates in the
surveillance group and in the non-surveillance control group were
100% and 65%, respectively (P¼ 0.029) (Figure 1). CRC-related
5-year mortalities were 0% and 26% in the surveillance and
non-surveillance groups, respectively (P¼ 0.042) (Figure 1). In
addition, a multivariate Cox regression analysis, including type of
IBD, concurrent primary sclerosing cholangitis, age at CRC
diagnosis, and co-morbidity as co-variables confirmed the
association between colonoscopic surveillance and improved
survival with reduced CRC-related mortality; however, this did
not reach statistical significance (P¼ 0.10) (Table 2).
Eleven patients in the non-surveillance group were diagnosed
with IBD and CRC simultaneously. Exclusion from analysis of
these patients strengthens the effect. The 5-year overall mortality is
0% in the surveillance group and 36% in the non-surveillance
group (P¼ 0.02). For CRC-related mortality, these percentages are
0% and 29% (P¼ 0.03). This effect also remains visible in the
multivariate analysis, although again it is not statistically
significant (Table 2).
Surveillance improves CRC-related survival in IBD
MWMD Lutgens et al
1672
British Journal of Cancer (2009) 101(10), 1671 – 1675 & 2009 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
In 10 out of 149 patients (7%), we did not have information
regarding 5-ASA prescription. This leaves 139 patients for analysis,
of whom 119 (86%) have used a 5-ASA preparation during the
course of their disease. Of these 119 patients, 64 (54%) used 5-ASA
medication for more than three-quarters of their disease dura-
tion. Nevertheless, all these patients developed CRC despite
the chemopreventive nature of 5-ASAs. As mentioned earlier,
4 out of 149 patients were excluded when evaluating survival
because they were lost to follow-up directly after CRC diagnosis.
Therefore, 135 patients remain for 5-ASA analysis between groups.
Twenty patients were in the surveillance group and 115 in the non-
surveillance group. All 20 patients (100%) in the surveillance
group had used 5-ASA preparations during their disease. In the
non-surveillance group, 96 out of 115 (77%) had used 5-ASA
preparations. This difference showed a trend but was not
statistically significant (P¼ 0.08). Furthermore, when included in
the multivariate cox regression analysis, it has no influence on
survival (P¼ 0.96), whereas the effect of surveillance (P¼ 0.098)
remains unchanged.
Tumour stages of the two groups are separately shown in
Table 3. Tumours were staged by a pathologist on the resection
specimen in 138 patients (93%) according to the TNM classifica-
tion. Information on TNM stage could not be retrieved in 11
patients (7%) for the following reasons: either the patients were
not operated on because of metastatic disease (n¼ 6), or a fully
detailed pathology report of resection specimen was not retrievable
(n¼ 5). In patients from the surveillance group, the observed
number of lower-stage tumours was higher than the expected
number. This effect was statistically significant when Stage 0 and 1
tumours were compared with all higher stages between the two
groups. In the surveillance group, 12 patients (52%) had Stage
0 and 1 tumours compared with 28 patients (24%) in the non-
surveillance group (P¼ 0.004). Moreover, the same effect was also
observed in the opposite direction with a statistically significantly
lower number of patients with Stages 3B-C and 4 tumours: four
patients (17%) in the surveillance group compared with 48 patients
(42%) in the non-surveillance group (P¼ 0.049).
Despite surveillance, four cancers in the surveillance group were
diagnosed as a consequence of new or altered symptoms of disease.
These so-called interval cancers had varying tumour stages:
T1N0M0, T2N1M0, T3N0M0, and T4N0M0. The interval since last
surveillance colonoscopy was 10, 14, 8, and 7 months, respectively,
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Figure 1 Survival analysis for CRC-related and overall mortality. The
Tarone–Ware test of equality of survival distribution was used to compare
survival between the two groups. CRC-related mortality is presented by
solid squares and line. Overall mortality is presented by outlined squares
and line. For CRC-related mortality, the 5-year survival in the surveillance
group (solid squares) was 100% compared with 74% in the non-
surveillance group (solid black line) (P¼ 0.029); the primary end point
was date of death due to CRC; cases were censored for date of end of
study, date of death related to any other primary malignancy, date of death
related to colectomy, date of death by any other cause, and date of lost to
follow-up. For overall mortality, the 5-year survival in the surveillance group
(outlined squares) was 100% compared with 65% in the non-surveillance
group (outlined line; P¼ 0.042); the primary end point was date of death;
cases were censored for date of end of study period and date of lost to
follow-up. CRC, colorectal cancer.
Table 2 Multivariate cox regression analysis: mortality due to CRC
Variable P-value P-valuea
Type of IBD 0.80 0.74
Age at CRC diagnosis (years) 0.55 0.71
Co-morbidity 0.74 0.64
Primary sclerosing cholangitis 0.16 0.10
Surveillance 0.10 0.08
Abbreviations: CRC¼ colorectal cancer; IBD¼ inflammatory bowel disease. aExclu-
sion of 11 patients with simultaneous diagnoses of IBD and CRC.
Table 1 Patient characteristics
Surveillance group
N¼ 23
Non-surveillance
group N¼ 126 P-value
IBD
Ulcerative colitis 18 (78%) 71 (56%) 0.053
Crohn’s disease 5 (22%) 54 (43%)
Indeterminate colitis 0 (0%) 1 (1%)
Gender
Male 17 (74%) 72 (57%) 0.132
Female 6 (26%) 54 (43%)
Co-morbidity 3 (13%) 29 (23%) 0.410
Median age at IBD-diagnosis (years) 26 (9–50) 30 (6–83) 0.148
Median age at CRC-diagnosis (years) 48 (38–71) 49 (21–85) 0.986
PSC 2 (9%) 17 (14%) 0.739
Mean interval between onset of IBD symptoms and diagnosis of CRC (months) 273 (15–541) 231 (0–536) 0.143
Mean follow-up time after CRC (months) 57 (0–188)* 51 (0–235)* 0.635
Abbreviations: CRC¼ colorectal cancer; IBD¼ inflammatory bowel disease; PSC¼ primary sclerosing cholangitis. *Four patients were lost to follow-up immediately after
diagnosis of CRC and were not included in survival analyses.
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and the patients were on 1-, 2-, 1, and 3-yearly intervals of
surveillance colonoscopies.
DISCUSSION
This series shows an improved survival in IBD patients who
developed CRC and in whom colonoscopic surveillance was
performed. It provides evidence showing the efficacy of surveil-
lance on CRC-related mortality with sufficient numbers of patients
with IBD-associated CRC. CRC-related mortality was significantly
lower in the surveillance group, with a 5-year survival rate of 100%
in the surveillance group and 74% in the non-surveillance group.
This effect can be explained by the detection of earlier-stage CRC
in the surveillance group, which translates into a better prognosis.
This report adds to the relatively small body of evidence,
indicating survival benefit through a surveillance strategy in
ulcerative colitis. We feel that it is prudent to join the ulcerative
colitis and Crohn’s colitis data, because there is increasing
evidence that the pathogenesis and natural behaviour of inflam-
mation-associated dysplasia in ulcerative colitis and Crohn’s
disease do not differ, and the risk of CRC is increased in both
(1,2). A recent systematic review (Collins et al, 2006) by the
Cochrane collaboration detected only three papers (Lashner et al,
1990; Choi et al, 1993; Karlen et al, 1998) that properly addressed
the question of surveillance effectiveness for patients with
ulcerative colitis. Other surveillance studies lacked valid control
groups (Rosenstock et al, 1985; Lofberg et al, 1990; Nugent et al,
1991; Jonsson et al, 1994; Friedman et al, 2001; Biasco et al, 2002;
Hata et al, 2003) or were not designed to answer this question
(Eaden et al, 2000). The reviewers of the Cochrane paper
concluded that all three publications pointed towards a beneficial
effect of surveillance on survival, but that the evidence was
indirect. Lashner et al (1990) showed an improved overall survival
in the surveillance group, but were unable to show that this was
secondary to a reduced CRC-related mortality. Similarly, they
could not find a difference in tumour stage between the two
groups. Choi et al (1993) published a small series of 41 patients
who developed CRC associated with ulcerative colitis, of whom 19
were in a colonoscopic surveillance programme and 22 were not.
In their series, as in ours, CRC was detected at a significantly
earlier stage in patients who had undergone colonoscopic
surveillance. Karlen et al, (1998) identified a trend towards a
protective effect of colonoscopic surveillance.
The strength of the current series lies in the high number of
cases with IBD-associated CRC available for analysis and the strict
criteria for inclusion in the surveillance group. Moreover, no
differences between the two groups in age at cancer diagnosis,
length of follow-up, and interval between onset of IBD and CRC
diagnosis were found, eliminating confounding from differences
in these variables (Table 1). The multivariate analysis confirmed
the association between colonocopic surveillance and improved
survival, but failed to reach statistical significance most probably
because of a type II error resulting from multiple variables in the
analysis (Table 2). The putative additional effect of smoking or
alcohol could not be evaluated in this analysis because of high
percentages of missing values.
Selection is a potential bias that needs consideration. Patients
who presented with diarrhoea or rectal bleeding and were
subsequently diagnosed with both IBD and CRC could very well
have affected the observed results. These patients would not have
participated in an endoscopic surveillance programme and were
probably only detected with IBD because of their CRC-related
symptoms. Eleven patients in our series were simultaneously
diagnosed with IBD and CRC. However, our results for CRC-
related tumour stage and mortality between groups did not change
when patients whose interval between diagnosis of IBD and CRC
was less than 1 year were excluded from the analysis. This is not
surprising as these patients were probably not different from the
patient group that did not undergo surveillance. It seems likely
that these individuals did not seek medical care for their condition
because of the absence of symptoms, and presented some years
after the start of the disease because of symptoms that were found
to be (at least partly) CRC related.
It is well recognised that 5-ASA is thought to be chemopreven-
tive for neoplasia. We collected data on medication use in all
patients. However, the retrospective design of our data collection
warrants us to be careful with its interpretation. Not all physicians
meticulously registered the exact duration of medication usage,
nor did we have insight into medication adherence.
Lead-time bias is known to influence screening and surveillance
data (Kramer, 2004). However, lead-time bias only occurs if the
intervention (in this case earlier tumour detection) does not affect
the terminal event (in this case mortality by CRC). In the case of
CRC, lead-time bias is probably not a significant problem, as
earlier diagnosis of CRC at a more favourable stage does improve
survival in a beneficial manner (Ries et al, 2007; Levin et al, 2008).
Others have questioned the importance of lead-time bias in CRC-
screening studies as well (Ransohoff and Lang, 1991).
Because of the lack of randomisation, volunteer bias might have
influenced results. The patients in the surveillance group could
have been more health conscious, leading to an earlier diagnosis of
CRC. In our study, however, the mean duration of disease until
CRC detection was longer in the surveillance group (22.7 vs 19.3
years). Therefore, it is not very likely that volunteer bias had a
major role in this study.
Four cancers in the surveillance group were found to be interval
cancers. This has been observed by others as well (Choi et al,
1993). We did not extract information on the exact number of
biopsies for each surveillance colonoscopy separately and there-
fore cannot comment upon whether these interval cancers may be
attributable to sub-optimal practice during the previous surveil-
lance colonoscopy. The occurrence of altered bowel symptoms
may lead to a diagnosis of CRC. Whether interval cancers are due
Table 3 Tumour stages
AJCC tumour stage
Non-surveillance
N¼ 121
Surveillance
N¼23 P-value
0 T in situ 9 2 0.689
1 T1, T2, N0, M0 19 10 0.008
2A T3, N0, M0 40 4 0.135
2B T4, N0, M0 2 1 0.409
3A T1, T2, N1, M0 3 2 0.180
3B T3, T4, N1, M0 14 2 1.000
3C Any T, N2, M0 12 0 0.215
4 M1 22 2 0.367
Abbreviation: AJCC¼American Joint Committee on Cancer. AJCC staging system 6th edition (12;13). Five tumours were not classifiable under AJCC Staging: 2 TxN0M0,
2 TxNxMx, and 1 TxNxM0.
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to a failure of detection during previous colonoscopy or to a rapid
progression of cancer is difficult to determine. Back-to-back
colonoscopy in patients without IBD has shown that the miss rate
for adenomas is 6–27%, which, among others, depends on
adenoma size (Rex et al, 1997). In addition, in all four of these
patients, unifocal low-grade dysplasia (LGD) had been diagnosed
before the diagnosis of CRC in a part of the colon close to the
location at which subsequently CRC was detected. Therefore,
either the CRC was missed at the previous colonoscopy or LGD
had progressed towards CRC between the two colonoscopies. Most
clinicians recommend colectomy for high-grade dysplasia; how-
ever, management for LGD is controversial. Only 5% of Dutch
gastroenterologists recommend colectomy for unifocal LGD.
A little under 30% of Dutch gastroenterologists recommend
colectomy in the case of multi-focal LGD (van Rijn et al, 2009).
Finally, referral centre bias deserves attention. All included cases
in this study were primarily treated in or referred to tertiary
university medical centres, which may have led to the introduction
of bias towards patients with more severe disease. Regarding the
level of risk of CRC in IBD patients, this kind of bias might be of
major importance, but it is less clear how this may affect the main
outcome of this study as index and control patients all originate
from referral hospitals. Although it is true that the results from this
study cannot be translated to the general IBD population
unequivocally, to date, no study exists comparing survival
outcome between IBD patients from referral centres and popula-
tion-based cohorts undergoing surveillance.
In conclusion, the patients in the surveillance group
showed statistically significant lower CRC-related mortality and
more favourable tumour stages. The evidence for improved
survival in this paper strengthens the notion that colonos-
copic surveillance in patients with longstanding IBD is beneficial
and should be performed in patients with a presumed high-risk
profile.
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